MDBH

Business Context and Reporting Period

Company: MDB Capital Holdings, LLC (MDBH)
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2025
Business Overview: MDB is a holding company operating through two primary segments: (1) Broker Dealer & Intellectual Property Services (Public Ventures and PatentVest) and (2) Technology Development (MDB Minnesota One). Notably, the company deconsolidated its former majority-owned subsidiary, eXoZymes, effective November 14, 2024, following eXoZymes' IPO, and now accounts for it as an equity method investment.

Key Financial Metrics

Material Changes vs. Prior Period

• Deconsolidation of eXoZymes: The most significant change is the removal of eXoZymes from consolidated operations. This resulted in a 100% reduction in Research and Development (R&D) costs for the three and nine months ended September 30, 2025, compared to the prior year.
• Operating Income Volatility: For the three months ended September 30, 2025, operating income turned positive ($1.25M) compared to a loss of $(0.61M) in the prior year, driven primarily by a $1.23M unrealized gain on investment securities held by the broker-dealer. Conversely, for the nine-month period, operating income declined to $178,570 from $1.01M in the prior year due to a $2.43M unrealized loss on investment securities.
• Expense Reduction: Total operating costs decreased by 38.2% for the three months and 24.4% for the nine months compared to the prior year, largely due to the deconsolidation of eXoZymes and reduced compensation expenses.
• Equity Method Investment: The company recorded an equity in loss of $(1.07M) for the quarter and $(3.05M) for the nine months related to its remaining stake in eXoZymes.

Guidance, Outlook, Risks, and Unusual Items

• Management Commentary: Management attributes the decrease in R&D and general administrative costs to the deconsolidation of eXoZymes. The broker-dealer segment saw increased clearing charges and IT costs due to the implementation of self-clearing operations.
• Unusual Items:
  • Stock-Based Compensation Modification: In April 2025, the company exchanged 3.6 million RSUs for stock options. This modification resulted in a decrease in aggregate fair value, requiring no incremental compensation costs.
  • Warrant Receipts: The company received warrants valued at $990,426 as part of an investment banking deal, recorded as a non-cash investing activity.
• Risks and Contingencies:
  • Internal Controls: The company disclosed material weaknesses in internal control over financial reporting. While remediation is ongoing, management concluded that disclosure controls were not effective as of September 30, 2025.
  • Regulatory Capital: The broker-dealer subsidiary (Public Ventures) must maintain minimum net capital of $250,000 plus 2% of customer debits. As of September 30, 2025, net capital was $7.78M, well in excess of requirements.
  • Legislative Impact: The company is evaluating the impact of the "One Big Beautiful Bill Act" (OBBBA) signed on July 4, 2025, on its tax provision.

Investor Verification Checklist

• Equity Method Valuation: Verify the carrying value of the eXoZymes investment ($38.7M) and the methodology used to calculate the equity in loss, given the recent IPO and ownership dilution.
• Investment Securities Volatility: Review the composition of the $4.4M investment securities portfolio and the sensitivity of unrealized gains/losses to market volatility, as this significantly impacts operating income.
• Internal Control Remediation: Assess the timeline and specific steps for remediation of the disclosed material weaknesses in internal controls over financial reporting.
• Liquidity Runway: Confirm the sufficiency of the $15.1M cash balance to fund ongoing operations, given the consistent net losses and cash burn from operating activities ($5.3M for the nine months).
• Related Party Transactions: Review the $1.38M in related party operating expenses and the $283k in related party receivables to ensure arm's-length terms.